Targeting depression: primary care tips and tools.
> THE CASE
As you get ready to see your next patient, 52-year-old Jim M, you see in his chart that during an annual routine nurse screening (per office protocol), he scored positive for depressed mood/anhedonia on the Patient Health Questionnaire-2 (PHQ-2) and scored a 21 out of 27 on the full version (PHQ-9), suggesting that he has severe major depressive disorder and that antidepressants should be considered.
When you enter the exam room, you notice his sad expression, poor eye contact, and stooped posture. Mr. M says his wife "made him" come to see you. He reports low energy and not wanting to leave his house, which started about a year earlier after he lost his job. When you discuss his job loss and the impact it has had on him, he sheepishly admits to sometimes thinking that things would be better if he were dead. Upon further questioning, you learn that he does not have suicidal intentions or plans.
O HOW WOULD YOU PROCEED WITH THIS PATIENT?
Depression is the most common mental health complaint in primary care settings; in 2015, an estimated 16.1 million (6.7%) adults in the United States ages 18 or older had at least one depressive episode in the past year. (1) Depression results in significant health, work, and social life impairments, (2) and comorbid anxiety is highly prevalent in patients with depression.
Primary care physicians see almost twice as many mental health patients as psychiatrists (3) due to barriers in behavioral health treatment (such as wait times, cost, and stigma) and the fact that primary care physicians often provide first-line access to behavioral health resources. Depression is caused by biological, psychological, and social factors, and primary care physicians are ideally positioned to develop therapeutic, healing relationships with patients that coincide with the biopsychosocial model of the disease. (4)
This review will provide some useful tips and tools to ensure that these patients get the care they need.
DEPRESSION? OR ARE OTHER FACTORS AT PLAY?
Major depressive disorder (MDD) is defined as a clinically significant change in mood that lasts at least 2 weeks. (5) The main symptoms of MDD include depressed mood and markedly diminished interest or pleasure; additional symptoms may include reduced self-esteem, weight/appetite changes, fatigue or reduced energy, guilt/worthlessness, decreased activity, poor concentration, and suicidal thinking. (5) To meet the criteria for a diagnosis of MDD, patients must experience symptoms for most of the day, nearly every day. (Dysthymia or persistent depressive disorder is a type of depression that is milder and more chronic than MDD, but does not have as many symptoms as MDD.) The focus of this article will be on MDD.
Shared symptoms with other disorders
Depression often displays some of the same symptoms as bereavement disorder and adjustment disorder, as well as other conditions.
* Grief over loss and depressive symptoms circumscribed to a stressor are considered bereavement disorder and adjustment disorder, respectively. These disorders are usually limited to weeks or months as the patient adapts to his/her particular situation.
* Organic problems such as nutritional deficiencies and sleep apnea can cause, exacerbate, or mimic depression (TABLE 16). Pain and depression are often associated, in that chronic pain can precipitate or perpetuate depression. (7)
* Bipolar disorder consists of both depressive and manic episodes; patients may be misdiagnosed and treated for depression alone.
* Substance intoxication or withdrawal can precipitate or perpetuate depression. A period of abstinence of at least one month may be necessary to see if depressive symptoms persist or resolve.
* Premenstrual dysphoric disorder is defined as a period of depressed mood that is limited to the final week before the onset of menses and resolves in the week post-menses.
HOW TO MAKE THE DIAGNOSIS
Inquiring about prolonged feelings of sadness and/or lack of enjoyment in activities is an effective way to begin the screening process for depression. (8) Screening tools such as the PHQ-9 (TABLE 29), Beck Depression Inventory, Hamilton Rating Scale for Depression, and Geriatric Depression Scale are useful when combined with a clinical interview. Another useful tool is the Mood Disorder Questionnaire, which can help one determine if a patient is suffering from depression or bipolar disorder. It's available at: http://www. dbsalliance.org/pdfs/MDQ.pdf. (Asking about a history of consecutive days of elevated, expansive, or irritable mood accompanied by increased activity or energy can also provide valuable insight.)
For its part, the US Preventive Services Task Force recommends screening adults for depression when adequate systems are in place (eg, referrals to settings that can provide necessary care) so as "to assure accurate diagnosis, effective treatment, and follow-up." (10-12)
* Assessing severity. Asking about functional impairments at work and at home and with academics and relationships will help determine severity, as will inquiring about a patient's past or current suicidal thoughts. About two-thirds of all patients with depression contemplate suicide and 10% to 15% will attempt suicide. (13)
There is no evidence that inquiring about thoughts of death or suicide exacerbates suicidal risk. (14,15) Confirming a diagnosis of MDD may require multiple visits, but should not delay treatment.
MAKING THE MOST OF THE TOOLS AT YOUR DISPOSAL
As a family physician (FP), you are especially well positioned to help patients suffering from MDD by offering education, counseling, and support; prescribing antidepressants; and coordinating care. Collaboration with behavioral health teams may be beneficial, especially in complex and treatment-resistant cases.
* Counseling, alone or combined with pharmacotherapy, may improve patient outcomes. (16,17) A first step may be recommending behavior modifications (such as adequate sleep, exercise, and a healthy diet). FPs can learn to utilize several counseling techniques, such as motivational interviewing, solution-focused therapy, and supportive therapy, for a variety of clinical situations in which behavioral change would be helpful. (18) Establishing a therapeutic alliance through empathy and creating treatment expectations are key to helping patients overcome depression. (19,20) Referral to a therapist can help identify and manage psychosocial factors that are often inherent in depression. Explaining to the patient that depression is best improved with a combination of medication and therapy is often helpful in motivating the patient to see a therapist.
* Selecting an antidepressant. There is insufficient evidence to show differences in remission rates or times to remission among antidepressants, (21) so medication choice involves balancing factors such as cost, previous treatments, adverse effects, and comorbid conditions (table 322). A recent systematic review and meta-analysis involving 66 studies and more than 15,000 patients found tricyclic/tetracyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) to have the best evidence for treatment of depression in the primary care setting. (23) Ask the patient about previous antidepressant prescriptions they were given, if any, and weigh the benefits and adverse effects with the patient.
Patients may notice a partial response as early as one to 2 weeks after starting treatment with antidepressants, but it's important to tell them that a full response can take up to 4 to 6 weeks. The goal of treatment is remission of depressive symptoms, which is defined as scoring below the cutoff point on a validated depression scale, such as less than 5 on the PHQ-9. (24) It's advisable to increase the antidepressant dose if the patient has a partial response and switch to a new class if the patient has no response or severe adverse effects.
Antidepressants should be maintained for at least 6 months or the length of a previous episode, whichever is greater. (24) Prophylactic treatment should be considered for patients who have had severe episodes in the past (eg, a history of suicidal ideations and/or past hospitalizations). If an antidepressant is discontinued, it should be tapered over one to 2 weeks to minimize the risk of discontinuation syndrome (flu-like symptoms, nausea, insomnia, and hyperarousal). There is a lack of consistent evidence for the use of St. John's wort, and as such, it is not recommended. (24)
* Adjunct medications can also be used when remission does not occur after 8 to 12 weeks of maximum antidepressant doses. Insomnia, which is a common complaint in patients with MDD, can be treated with trazodone (an off-label indication), diphenhydramine, or melatonin. (See "Insomnia: Getting to the cause, facilitating relief" on page 216.) Benzodiazepines and other hypnotics (eg, Zolpidem) can be used initially until antidepressants have had time to become effective. Antipsychotics such as aripiprazole, risperidone, quetiapine, and ziprasidone can be used to treat psychotic symptoms of depression or boost antidepressant effectiveness. (25) Lithium and thyroxine are effective for treatment-resistant depression. (26) Nutraceuticals such as S-Adenosyl-L-methionine, methylfolate, omega-3, and vitamin D can reduce depressive symptoms when combined with an antidepressant. (27)
There is some evidence to support combining 2 antidepressants from different classes (eg, an SSRI plus a serotonin-norepinephrine reuptake inhibitor [SNRI] or norepinephrinedopamine reuptake inhibitor, or an SNRI plus a noradrenergic and specific serotonergic antidepressant) when adjunct therapy has proven ineffective. (28)
Inpatient psychiatric admission is warranted in severe cases, such as when a patient has active suicidal intentions/plans or poor self-care.
Your critical role, even when depression is co-managed
Collaborative care for depression (patient contact with both primary and behavioral health care providers in the same clinic) significantly improves clinical outcomes at 6 months compared to primary care treatment alone. (29) Patients who have failed 2 therapeutic trials (at least 6-8 weeks of separate antidepressant treatments without response) are considered treatment-resistant. (30) Referral to a psychiatrist is appropriate in this setting to determine alternative treatment options.
Based on further conversation with Mr. M, you learn that he actually began exhibiting symptoms of depression (anhedonia, poor concentration, insomnia) years before he lost his job, but that he had considered the symptoms "normal" for his age. He reports that he didn't want to socialize with others anymore and harbors feelings of worthlessness. You tell him that you believe he is suffering from MDD and talk to him about some options for treatment. You decide together to begin a trial of escitalopram 10 mg/d, as it was covered by his insurance, has minimal adverse effects, and was a good match for his symptoms. You also educate and instruct Mr. M on self-management goals such as limiting alcohol intake, eating at least 2 meals a day, walking with his wife each evening, and following a regular sleep schedule. You discuss a safety plan with Mr. M, should his depressive symptoms worsen. Specifically, you tell him that if he begins to have suicidal intentions or plans, he should call 911 or go to the nearest emergency department.
Mr. M returns 4 weeks later and reports that his mood has slightly improved, as evidenced by a brighter affect and increased energy, so you increase the dose of escitalopram to 20 mg/d. At his third visit 4 weeks later, Mr. M discloses a remote history of trauma and current intermittent heavy drinking. After offering support and education and discussing his options, you refer Mr. M to a counselor in your clinic through a "warm handoff" (the counselor is brought briefly into the current session with the patient to meet and set up an appointment). During this time, he is given information about an outpatient substance abuse treatment group.
Mr. M's PHQ-9 improves by 8 points by his fourth visit 4 weeks later. He reports that he is still taking the escitalopram and you recommend he continue to take it. Mr. M tells you he's been seeing the counselor at your clinic every other week and that he has begun attending meetings with the substance abuse group. He also says that he and his wife go out for walks now and then. Mr. M says he feels as though he is a failure, prompting you to recommend that he explore the cognitive distortions (ie, inaccurate thoughts that reinforce negative feelings) with his therapist.
You schedule another appointment with Mr. M in 3 months to keep track of his progress. Fortunately, Mr. M's therapist works in the same clinic as you, so you can contact her to discuss his progress with therapy.
(1.) National Institute of Mental Health. Major depression among adults. National Institute of Mental Health Web site. Available at: http://www.nimh.nih.gov/health/statistics/prevalence/major-depression -among-adults.shtml. 2014. Accessed June 22, 2016.
(2.) Cameron C, Habert J, Anand L, et al. Optimizing the management of depression: primary care experience. Psychiatry Res. 2014; 220:S45-S57.
(3.) Wang PS, Lane M, Olfson M, et al. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005, 62:629-640.
(4.) Schotte CK, Van Den Bossche B, De Doncker D, et al. A biopsychosocial model as a guide for psychoeducation and treatment of depression. Depress Anxiety. 2006; 23:312-324.
(5.) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association, 2013:160-161.
(6.) Sadock Bl, Sadock VA. Kaplan and Sadock's Synopsis of Psychiatry. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003:830-834.
(7.) Fishbain DA, Cutler R, Rosomoff HL, et al. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain. 1997; 13:116-137.
(8.) Arroll B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ. 2003; 327:1144-1146.
(9.) Kroenke K, Spitzer RL, Williams IB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16: 606-613.
(10.) US Preventive Services Task Force. Depression in adults: Screening. US Preventive Services Task Force Web site. Available at: https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/depres sion-in-adults-screening. Accessed March 13, 2017.
(11.) Thombs BD, Ziegelstein RC. Does depression screening improve depression outcomes in primary care? BMJ. 2014; 348:g1253.
(12.) Siu AL. Bibbins-Domingo K, Grossman DC, et al. Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016; 315:380-387.
(13.) Sadock BJ, Sadock VA. Kaplan and Sadock's Synopsis of Psychiatry. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003:543.
(14.) Gould MS, Marrocco FA, Kleinman M, et al. Evaluating iatrogenic risk of youth suicide screening programs: a randomized controlled trial. JAMA. 2005; 293:1635-1643.
(15.) Eynan R, Bergmans Y, Antony I, et al. The effects of suicide ideation assessments on urges to self-harm and suicide. Crisis. 2014; 35:123-131.
(16.) Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry. 2004; 61:714-719.
(17.) Ishak WW, Ha K, Kapitanski N. et al. The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depression. Harv Rev Psychiatry. 2011; 19:277-289.
(18.) Raddock M, Martukovich R, Berko E, et al. 7 tools to help patients adopt healthier behaviors. J Fam Pract. 2015; 64:97-103.
(19.) Castonguay LG, Constantino Ml, Holtforth MG. The working alliance: Where are we and where should we go? Psychotherapy (Chic). 2006; 43:271-279.
(20.) Greenberg RP, Constantino MJ, Bruce N. Are patient expectations still relevant for psychotherapy process and outcome? Clin Psychol Rev. 2006; 26:657-678.
(21.) Warden D, Rush Al, Trivedi MH, et al. The STAR'D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007; 9:449-459.
(22.) Sadock BJ, Sadock VA. Kaplan and Sadock's Synopsis of Psychiatry. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003:558.
(23.) Linde K, Kriston L, Riicker G, et al. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann Fam Med. 2015; 13:69-79.
(24.) American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. 2010. Available at: http://psychiatryonline.org/pb/assets/raw/ sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed December 23, 2016.
(25.) Zhou X, Keitner GI, Qin B, et al. Atypical antipsychotic treatment for treatment-resistant depression: A systematic review and network meta-analysis. Int J Neuropsychopharmacol. 2015; 18:pyv060.
(26.) Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR'D report. Am J Psychiatry. 2006; 163:1519-1530; quiz 1665.
(27.) Sarris I, Murphy J, Mischoulon D, et al. Adjunctive nutraceuticals for depression: A systematic review and meta-analyses. Am J Psychiatry. 2016; 173:575-587.
(28.) Dodd S, Horgan D, Malhi GS, et al. To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord. 2005; 89:1-11.
(29.) Gilbody S. Bower P. Fletcher I, et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med. 2006; 166:2314-2321.
(30.) Papakostas GI, Fava M. Pharmacotherapy for Depression and Treatment-Resistant Depression. Hackensack, NI: World Scientific. 2010:4.
Michael Maksimowski, MD; Michael Raddock, MD
The MetroHealth System, Cleveland, Ohio
The authors reported no potential conflict of interest relevant to this article.
Michael Raddock, MD, 2500 MetroHealth Drive, Cleveland, OH 44109; email@example.com.
TABLE 1 Potential organic causes of depressive symptoms (6) Causes Tests Anemia, leukocytosis Complete blood count Metabolic/electrolyte Metabolic/chemistry panel abnormalities, poor renal function Hormonal abnormalities TSH, ACTH stimulation test, dexamethasone suppression test Substance use Urine drug screen, blood alcohol level Pregnancy Urine hCG Nutritional deficiencies Vitamin B12, vitamin D Sleep apnea Polysomnogram ACTH, adrenocorticotropic hormone; hCG, human chorionic gonadotropin; TSH, thyroid stimulating hormone. TABLE 2 Patient Health Questionnaire (PHQ-9) (9) Question Response Over the last 2 weeks, Not at Several More than Nearly how often have you been all days half the every bothered by any of the days day following problems? (use "[check]" to indicate your answer) 1. Little interest or 0 1 2 3 pleasure in doing things 2. Feeling down, 0 1 2 3 depressed, or hopeless 3. Trouble falling or 0 1 2 3 staying asleep, or sleeping too much 4. Feeling tired or 0 1 2 3 having little energy 5. Poor appetite or 0 1 2 3 overeating 6. Feeling bad about 0 1 2 3 yourself-or that you are a failure or have let yourself or your family down 7. Trouble concentrating 0 1 2 3 on things, such as reading the newspaper or watching television 8. Moving or speaking so 0 1 2 3 slowly that other people may have noticed, or being so fidgety or restless that you have been moving around a lot more than usual 9. Thoughts that you 0 1 2 3 would be better off dead, or of hurting yourself in some way For office coding 0 + __ + __ + __ = Total score: __ If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people? Not difficult Somewhat Very Extremely at all difficult difficult difficult     Score interpretation 1 to 4: No depression. 5 to 9: Mild depression; watchful waiting; consider repeating PHQ-9 at follow-up visit. 10 to 14: Moderate depression; consider counseling and/or pharmacotherapy. 15 to 19: Moderately severe depression; start pharmacotherapy and/or counseling. 20 to 27: Severe depression; start pharmacotherapy; hospitalize if actively suicidal; refer to behavioral health specialist if patient has severe impairment or poor response to treatment. TABLE 3 Commonly used antidepressants (22) Class Types (usual Unique properties daily dosing) TCAs Amitriptyline Effective in patients with (100-300 mg) chronic pain, diabetic neuropathy, migraines, and Nortriptyline fibromyalgia. (40-200 mg) Imipramine (50-150 mg) SSRIs Citalopram Generally safe to use in (20-60 mg) pregnancy. Citalopram can cause QTc prolongation. Escitalopram Good for comorbid anxiety. (10-20 mg) Sertraline (50-200 mg) Fluoxetine (10-40 mg) Paroxetine (20-50 mg) SNRIs Duloxetine Good for patients who are also (30-60 mg) suffering from neuropathic pain. Venlafaxine is good for Venlafaxine comorbid anxiety and comes in (150-375 mg) regular-and extended-release formulations. NDRIs Bupropion Good for ADHD-like symptoms (200-400 mg) and tobacco users; no sexual adverse effects. NaSSAs Mirtazapine Good for insomnia and poor (15-30 mg) appetite; no sexual adverse effects. Class Types(usual Common adverse effects daily dosing) TCAs Amitriptyline Anticholinergic effects (100-300 mg) include sedation, constipation, and urinary Nortriptyline retention. Can cause (40-200 mg) orthostatic hypotension. Risk of fatal arrhythmia in Imipramine overdose. (50-150 mg) SSRIs Citalopram Adverse effects include (20-60 mg) decreased sexual libido; gastrointestinal problems Escitalopram (diarrhea, nausea, vomiting); (10-20 mg) emotional blunting; and bruising (inhibition of Sertraline platelet function). When (50-200 mg) taking other serotonergic medications (eg, tramadol, Fluoxetine odansetron, triptans), (10-40 mg) serotonin syndrome (diarrhea, restlessness, autonomic Paroxetine instability, rigidity, (20-50 mg) myoclonus) is also a concern. SNRIs Duloxetine In addition to SSRI adverse (30-60 mg) effects listed above, SNRIs can cause elevated blood Venlafaxine pressure. (150-375 mg) NDRIs Bupropion Headaches, insomnia, tremors, (200-400 mg) lowers seizure threshold, worsens anxiety. NaSSAs Mirtazapine Somnolence, weight gain. (15-30 mg) ADHD, attention-deficit-hyperactivity disorder; NaSSAs, noradrenergic and specific serotonergic antidepressants; NDRIs, norepinephrine- dopamine reuptake inhibitors; SNRIs, serotonin-norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||BEHAVIORAL HEALTH CONSULT|
|Publication:||Journal of Family Practice|
|Date:||Apr 1, 2017|
|Previous Article:||The case.|
|Next Article:||When can exercise supplant surgery for degenerative meniscal tears? Patients with a medial, degenerative meniscal tear and a minimal history of...|